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recipients. The impairments of flow-mediated vasodilation andFlow-mediated vasodilation and distensibility of the brachial
distensibility are not attributable to a diminished brachial ar-artery in renal allograft recipients.
tery vasodilator capacity, because endothelium-independentBackground. Alterations of large artery function and struc-
vasodilation was preserved in renal allograft recipients.ture are frequently observed in renal allograft recipients. How-
ever, endothelial function has not yet been assessed in this
population.
Methods. Flow-mediated vasodilation is a useful index of
Cardiovascular events are the leading cause of overallendothelial function. We measured the diameter and distensi-
morbidity and mortality observed in end-stage renal dis-bility of the brachial artery at rest using high-resolution ultra-
sound and Doppler frequency analysis of vessel wall move- ease and after kidney transplantation [1–4]. Alterations
ments in the M mode. Thereafter, changes in brachial artery of structure and function of large arteries associated with
diameter were measured during reactive hyperemia (after 4 disturbed cushioning function are major factors contrib-min of forearm occlusion) in 16 cyclosporine-treated renal allo-
uting to the increased cardiovascular morbidity in thesegraft recipients and 16 normal controls of similar age and sex
ratio. Nitroglycerin-mediated vasodilation was measured to as- patients. Several studies showed reduced distensibility
sess endothelium-independent vasodilation. Brachial artery and increased intima-media thickness of large arteries in
blood pressure was measured using an automatic sphygmoma- hemodialysis patients and in renal transplant recipients
nometer, and brachial artery flow was estimated using pulsed
[5–7].Doppler.
In the last decade, much interest focused on endothe-Results. Distensibility was reduced in renal allograft recipi-
ents (5.31 6 0.74 vs. 9.10 6 0.94 3 1023/kPa, P 5 0.003, mean 6 lial function. Disturbed endothelial function is a crucial
sem), while the brachial artery diameter at rest was higher factor in atherogenesis [8] and may be related to dis-
(4.13 6 0.14 vs. 3.25 6 0.14 mm, P , 0.001). Flow-mediated turbed vessel wall properties. Recent observations dem-vasodilation was significantly reduced in renal allograft recipi-
onstrate endothelial dysfunction in chronic renal failureents (0.13 6 0.08 vs. 0.60 6 0.08 mm or 3 6 2 vs. 19 6 3%,
[9] and in hemodialysis patients [10]. It has been shownboth P , 0.001). However, nitroglycerin-mediated vasodilation
was similar in renal allograft recipients and controls (0.76 6 that uremia is associated with an accumulation of an
0.10 vs. 0.77 6 0.09 mm, NS, or 19 6 3 vs. 22 6 2%, NS). endogenous inhibitor of nitric oxide synthesis [11]. These
There were no significant differences in brachial artery flow at
observations suggest that chronic uremia may impairrest and during reactive hyperemia between both groups. The
endothelial function. However, after reversal of uremiaimpairments of flow-mediated vasodilation and distensibility
in renal allograft recipients remained significant after correc- by successful renal transplantation, endothelial function
tion for serum cholesterol, creatinine, parathyroid hormone has not yet been assessed. Moreover, arterial stiffening
concentrations, end-diastolic diameter, as well as blood pres- frequently observed in end-stage renal failure [5–7] maysure levels, and were also present in eight renal allograft recipi-
be associated with a reduced vasodilator capacity in-ents not treated with cyclosporine. Flow-mediated vasodilation
terfering with endothelial-mediated vasodilation. A pos-was not related to distensibility in either group.
Conclusions. The results show impaired endothelial func- sible relationship between disturbed endothelial function
tion and reduced brachial artery distensibility in renal allograft and altered mechanical vessel wall properties has not
yet been elucidated.
Flow-mediated vasodilation and arterial distensibilityKey words: transplantation, endothelial cell, hypercholesterol, vasodi-
lation, hypertension, cardiovascular disease. have been shown to be useful indices of endothelial func-
tion [12–14] and mechanical vessel wall properties [15,
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Table 1. Demographic data additional renal transplant patients treated with azathio-
prine (average dose 88 6 12 mg/day) and prednisoloneNTX CON P
(average dose 4 6 1 mg/day) who did not receiveAge years 4262 41 62 NS
Male/female 11/5 7/9 NS cyclosporine or tacrolimus were studied. These patients
Smokers/nonsmokers 6/10 5/11 NS fulfilled the same inclusion and exclusion criteria as theBody mass index kg/m2 2561 23 61 0.045
cyclosporine-treated patients. Antihypertensive treat-
Displayed are demographic data of renal allograft recipients (NTX) and nor-
ment consisted of loop diuretics in three patients, bmal control subjects (CON). Body mass index was calculated as weight/(height)2.
The abbreviation NS is: not significant. blockers in five patients, calcium antagonists in two pa-
tients, and ACE inhibitors in one patient. These eight
patients were compared with eight of the cyclosporine-
bility in renal allograft recipients with stable graft func- treated renal allograft recipients matched for age, sex,
tion and without clinical evidence of atherosclerotic dis- and graft function.
ease, and in normal control subjects, and to assess a The studies were approved by the Institutional Review
possible relationship between the two. Board on Human Investigation, and written informed
consent was obtained.
METHODS
MeasurementsPatients
Only patients without an arteriovenous fistula or pre-Sixteen renal transplant recipients and 16 normoten-
vious vascular surgery on the right arm were included insive healthy controls were included in the study. Inclu-
the study. Brachial artery blood pressure was measuredsion criteria for the patients were stable graft function
using an automatic sphygmomanometer (Critikon Dina-with serum creatinine concentrations of less than 2 mg/
map model 1846 SX; Critikon, Tampa, FL, USA). Heartdl, systolic blood pressure less than 160 mm Hg and
rate was determined using an ECG monitor. The brachialdiastolic blood pressure less than 90 mm Hg. Exclusion
criteria were clinical evidence of atherosclerotic disease, artery of the right arm was visualized in a longitudinal
diabetes mellitus, heart failure, abnormal electrocardio- section 2 to 6 cm above the elbow using a 7.5 Mhz linear
gram (ECG), or an abnormal treadmill exercise test. array transducer and a standard Toshiba Sonolayer a
Patients as well as control subjects with evidence of SSA-270A system (Toshiba Medical Systems, Neuss,
plaque formation or calcifications in the carotid bifurca- Germany). The brachial artery was displayed in the B
tion, common carotid artery, or brachial artery, as ob- and in M modes. Vessel diameter and distention was
served by high-resolution ultrasound, were also ex- then analyzed using a multigate pulsed Doppler system.
cluded. Patients were 43 6 7 months (range 5 to 88 Low-frequency Doppler signals originating from the
months) after transplantation. Causes of end-stage renal
sample volumes coinciding with the anterior and poste-disease were chronic glomerulonephritis in seven cases,
rior vessel walls were processed. The positions of thechronic pyelonephritis in three cases, polycystic renal
sample volumes were continuously adjusted accordingdisease in two cases, Alport’s syndrome in one case,
to the displacement of the wall. The resolution for a 6.1hydronephrosis in one case, and unknown in two cases.
Mhz Doppler system is equivalent to a displacement ofAll patients received immunosuppressive treatment with
31.25 mm (assuming a speed of sound of 1525 m/second),cyclosporine (whole blood trough levels adjusted be-
which far exceeds the resolution capacity of a real-timetween 80 and 150 ng/ml, mean 105 6 11 mg/liter, high-
performance liquid chromatography method) and pred- scanner for static objects [5, 6]. Using the ECG trigger,
nisolone (average dose 7 6 1 mg/day). Five patients were the end-diastolic diameter and distention of the brachial
additionally treated with mycophenolate mofetile (dose artery were measured over three consecutive cardiac
range 1 to 2 g/day). Antihypertensive treatment con- cycles, and the results were averaged to a single value.
sisted of loop diuretics in eight patients, angiotensin- Coefficients of variation were 4.5 6 0.7% (N 5 26) for
converting enzyme (ACE) inhibitors in eight patients, the end-diastolic diameter and 9.6 6 1.6% (N 5 26) for
calcium antagonists in nine patients, and b blockers in the relative distention of the brachial artery. Standard
11 patients. One patient did not receive any antihyper-
laboratory assays were used to determine serum concen-tensive treatment.
trations of creatinine, total cholesterol, high-density lipo-The 16 healthy control subjects, not on any medica-
protein cholesterol, low-density lipoprotein (LDL) cho-tions, were matched for age. Subjects showing any abnor-
lesterol, triglycerides, and glucose, as well as hemoglobinmalities in routine physical examination, standard labo-
concentrations. Plasma intact (1–84) parathyroid hor-ratory tests, ECG, or chest x-ray were not included.
mone concentrations were determined using an radioim-Demographic data of patients and subjects are repre-
munoassay. The reference values for this assay are 12sented in Table 1.
To assess the effects of cyclosporine therapy, eight to 65 ng/liter.
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Table 2. Standard laboratory analysesProtocol
NTX CON PAll studies were performed between 8 and 12 a.m.
Hemoglobin g/dl 13.660.4 14.060.3 NSTwelve to 14 hours had elapsed between the measure-
Serum cholesterol mg/dl 289611 21169 ,0.001ments and the previous intake of cyclosporine or antihy-
HDL cholesterol mg/dl 6465 6262 NS
pertensive drugs. Measurements were taken in the su- LDL cholesterol mg/dl 18069 13167 0.002
Serum triglycerides mg/dl 191622 102611 0.001pine position after at least 15 minutes of rest. Two
Serum glucose mg/dl 9564 8163 0.02measurements of end-diastolic diameter and distention
Parathyroid hormone ng/liter 82614 2862 ,0.001
of the brachial artery at baseline were taken. The mea- Serum creatinine mg/dl 1.2060.14 0.8360.03 NS
surement site was at least 10 cm proximal to the site of The results of standard blood and serum laboratory analyses in renal transplant
recipients (NTX) and normal control subjects (CON) are shown. Abbreviationsforearm occlusion. A cuff placed on the forearm was
are: HDL, high density lipoprotein; LDL, low density lipoprotein; NS, not signifi-inflated at 300 mm Hg during four minutes. During the cant.
last minute of cuff inflation and at 1, 3, 5, 7 and 10
minutes after cuff release, further measurements of bra-
chial artery end-diastolic diameter were taken. Brachial
Table 3. Hemodynamic variables, brachial artery distensibility andartery blood flow at baseline and during the initial 15
endothelium-dependent and -independent vasodilation
seconds of reactive hyperemia was estimated using
NTX CON Ppulsed Doppler. Eleven minutes after cuff release, 400
Blood pressure mm Hgmg of glycerol trinitrate were administered sublingually,
Systolic 13666 120 62 0.007and further scans of the brachial artery were taken after
Diastolic 8062 74 62 NS
one, three, and five minutes. Pulse pressure mm Hg 5665 46 62 NS
Heart rate /min 7264 63 62 NS
BS diameter mm 4.160.14 3.3 60.14 ,0.001Analyses
BA relative distension % 2.060.3 2.7 60.3 0.04
From the end-diastolic diameter (d), the relative sys- DC 1023/kPa 5.360.7 9.1 60.9 0.003
FMD mm 0.1360.08 0.60 60.08 ,0.001tolic increase of vessel diameter (relative distention 5
NMD mm 0.7660.10 0.77 60.09 NSDd 3 d21) and from the systolic blood pressure and Baseline BA flow ml/min 88615 106632 NS
diastolic blood pressure, arterial wall distensibility was Peak BA flow ml/min 448688 441 652 NS
calculated [distensibility coefficient 5 2 Dd 3 d21 3 Displayed are values for systolic and diastolic blood pressure and pulse pres-
sure, heart rate, brachial artery (BA) diameter, relative distension and distensibil-(systolic blood pressure 2 diastolic blood pressure)21
ity coefficient (DC), brachial artery flow-mediated vasodilation (FMD) and glyc-
(1023 kPa)]. erol-trinitrate-mediated vasodilation (NMD) as well as brachial artery (BA)
blood flow at baseline and during reactive hyperemia in renal allograft recipientsFlow-mediated vasodilation was calculated as the max-
(NTX) and control subjects (CON). The abbreviation NS means not significant.
imum absolute and relative increase in brachial artery
end-diastolic diameter during reactive hyperemia. Nitro-
glycerin-mediated vasodilation was accordingly calcu-
lated as the maximum absolute and relative increase in All patients had stable allograft function. Serum creat-
brachial artery end-diastolic diameter after sublingual inine concentrations tended to be higher than in control
glycerol trinitrate. subjects, yet the difference did not reach statistical sig-
Statistical analysis was performed by Mann–Whitney nificance (Table 2). Total serum cholesterol and LDL
U-tests for continuous variables and by Fisher’s exact cholesterol concentrations were significantly elevated in
test for nominal variables. Additionally, analysis of co- patients, whereas high-density lipoprotein cholesterol
variance was performed for key variables. Correlation concentrations did not differ between patients and con-
analyses were performed using Spearman rank correla- trol subjects. Serum triglyceride and glucose concentra-
tion. Statistical significance was assumed at P , 0.05, tions were significantly elevated in patients. Serum intact
and NS means statistically not significant. Data are pre- (1–84) parathyroid hormone levels were significantly in-
sented as mean 6 sem. creased in patients. There was no significant difference
in hemoglobin concentrations between patients and sub-
jects.
RESULTS
Patients had higher systolic blood pressure values than
Comparison of cyclosporine-treated renal allograft controls, however, they did not differ significantly in
recipients and healthy control subjects diastolic blood pressure or pulse pressure (Table 3). The
heart rates did not differ significantly between theDemographic data of patients and control subjects are
shown in Table 1. There were no significant differences groups.
Brachial artery end-diastolic diameter at baseline wasin age, smoking habits, and sex ratio between groups.
Renal transplant recipients, however, had a slightly significantly higher in renal transplant recipients than in
control subjects. During reactive hyperemia, the increasehigher average body mass index.
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Fig. 1. Flow-mediated (FMD) and glycerol-trinitrate-mediated (NMD)
brachial artery dilation in renal transplant recipients ( ; NTX) and
healthy control subjects ( ) expressed in the percentage from baseline Fig. 2. Flow-mediated brachial artery dilation (FMD) plotted against
value. Flow-mediated vasodilation was impaired in NTX (*P , 0.001). the brachial artery distensibility coefficient (DC) in renal allograft recip-
However, endothelium-independent vasodilation as indicated by NMD ients (j, NTX) and control subjects (s, CON). FMD and DC were
was preserved in NTX. lower in NTX than in CON. FMD did not relate to DC in either group
(rho 5 0.46 for CON and rho 5 0.19 for NTX, both NS).
in brachial artery end-diastolic diameter (flow-mediated
0.02 m/second in controls; reactive hyperemia, 0.84 6
vasodilation) was significantly blunted in patients. This
0.21 m/second in patients vs. 0.81 6 0.09 m/second in
was true when diameter changes were expressed both
controls; NS). In the group of renal transplant recipients,
as absolute and as relative values (Fig. 1 and Table 3).
flow-mediated vasodilation was significantly lower than
In contrast, brachial artery vasodilation after sublingual in controls (3.4 6 1.8 vs. 14.3 6 2.8%, P , 0.02). Nitro-
glycerol trinitrate was similar in patients and control glycerin-induced vasodilation did not differ between
subjects. both groups (18.3 6 3.3% in patients vs. 21.9 6 2.4% in
In renal transplant recipients, the relative distention controls; NS).
and the distensibility coefficient of the brachial artery To assess the influence of potential confounding vari-
were significantly reduced as compared with control sub- ables on vessel wall properties, analysis of covariance
jects. was performed for key variables. Analysis of covariance
Brachial artery flow was comparable in patients and revealed that the difference in brachial artery flow-medi-
controls at baseline and during reactive hyperemia. Bra- ated vasodilation between patients and controls re-
chial artery mean blood flow velocity during reactive mained statistically significant (P 5 0.012) independent
hyperemia tended to be lower in patients than in control of body mass index (P 5 0.34), serum cholesterol (P 5
subjects, however, this was not statistically significant 0.17), triglyceride (P 5 0.023), glucose (P 5 0.24) and
(0.57 6 0.12 vs. 0.86 6 0.10 m/second, NS). It was consid- creatinine concentrations (P 5 0.49), parathyroid hor-
ered that the reduction of flow-mediated vasodilation mone levels (P 5 0.059), systolic (P 5 0.41) and diastolic
in renal transplant recipients as compared with healthy blood pressure (P 5 0.42), and brachial artery end-dia-
controls was due to differences in end-diastolic diameter stolic diameter (P 5 0.001). Similarly, analysis of covari-
and accordingly lower brachial artery mean blood flow ance demonstrated a statistically significant difference
velocity. To test this possibility, flow-mediated vasodila- in brachial artery distensibility coefficients between pa-
tion was compared in subgroups of eight renal transplant tients and controls (P 5 0.048) independent of body
recipients (age 41 6 4 years) and eight healthy control mass index (P 5 0.86), serum cholesterol (P 5 0.35),
subjects (age 38 6 3 years) matched for brachial artery triglyceride (P 5 0.50), glucose (P 5 0.08) and creatinine
end-diastolic diameter (3.72 6 0.11 vs. 3.63 6 0.12 mm, concentrations (P 5 0.69), parathyroid hormone levels
NS). Brachial artery blood flow velocities at baseline and (P 5 0.91), systolic (P 5 0.11) and diastolic (P 5 0.65)
during reactive hyperemia were similar in both groups blood pressures, and brachial artery end-diastolic diame-
ter (P 5 0.26).(baseline, 0.16 6 0.04 m/second in patients vs. 0.16 6
Hausberg et al: Post-transplant endothelial function and distensibility1108
Table 4. Comparison of cyclosporine-treated renal transplant DISCUSSION
recipients and patients without cyclosporine therapy
This study has two major findings. First, endothelial
NTX NTX, function as determined by flow-mediated vasodilation is1 CsA no CsA P
substantially impaired in asymptomatic renal allograft
Age years 4862 5265 NS
recipients despite preserved arterial vasodilator capacity.Serum creatinine mg/dl 1.1960.23 1.3360.21 NS
Serum cholesterol mg/dl 288631 245620 NS Second, these patients also have altered mechanical
Serum triglycerides mg/dl 189637 183629 NS properties of large arteries, as shown by a reduced bra-
Parathyroid hormone ng/liter 8169 80614 NS
chial artery distensibility.Blood pressure mm Hg
Systolic 142610 13866 NS The study shows reduced arterial distensibility in renal
Diastolic 7963 8264 NS transplant patients as previously observed in hemodialy-
BA diameter mm 4.260.2 4.260.4 NS
sis patients [5, 6]. Malyszko et al reported decreasedDC 1023/kPa 5.561.3 5.260.6 NS
FMD % 1.762.6 4.162.3 NS fibrinolytic activity and elevated levels of von Willebrand
NMD % 19.363.8 16.861.8 NS factor in renal allograft recipients, which may indicate
Baseline BA flow ml/min 96612 104617 NS
chronic endothelial injury [17]. Our study is the first, toPeak BA flow ml/min 480617 460652 NS
our knowledge, to demonstrate endothelial dysfunction,Displayed are demographic data, serum chemistry analyses and values for
systolic and diastolic blood pressure, brachial artery (BA) diameter and distensi- as indicated by substantially impaired flow-mediated va-
bility coefficient (DC), brachial artery flow-mediated vasodilation (FMD) and sodilation in these patients.glycerol-trinitrate-mediated vasodilation (NMD) as well as brachial artery (BA)
blood flow at baseline and during reactive hyperemia in renal allograft recipients None of the renal transplant recipients had overt ath-
(NTX) with and without cyclosporine (CsA) therapy. N 5 8 in each group. The
erosclerotic disease. Nevertheless, patients displayedabbreviation NS means not significant.
substantially impaired endothelial function and also dis-
turbed mechanical vessel wall properties. In vivo studies
show unequivocally that endothelial dysfunction is an
early event in atherogenesis. MacLenachan et al re-Correlation analyses
ported that maximal endothelial dysfunction is observedWe did not observe a significant correlation between
at coronary branch points, the sites most likely to developbrachial artery flow-mediated vasodilation and the dis-
atherosclerotic lesions [18]. It has been shown in cardiactensibility coefficient in either group (Fig. 2). The relative
transplant recipients that endothelial dysfunction pre-distention of the brachial artery was also not related to
cedes coronary artery occlusive disease [19]. Moreover,flow-mediated vasodilation in either group (rho 5 0.35,
healthy children at increased risk to develop atheroscle-NS, for control subjects and rho 5 0.27, NS, for patients).
rotic disease exhibit disturbed endothelial function [20].Despite the substantially higher end-diastolic diameter
Also, impaired cushioning function of large arteries ap-in patients as compared with controls, there was no rela-
pears to be related to atherosclerotic vessel wall changes
tionship between end-diastolic diameters and distensibil-
and leads to cardiac hypertrophy, which has recently
ity coefficients of the brachial artery in either group
been shown in patients with renal failure [7, 21]. Thus,
(rho 5 20.27, NS, for control subjects and rho 5 20.06, the alterations of endothelial function and arterial dis-
NS, for patients). We found a significant inverse correla- tensibility we observed in renal allograft recipients may
tion between brachial artery diameter and flow-mediated be predictors for the development of cardiovascular dis-
vasodilation in control subjects (rho 5 20.59, P 5 0.02), ease in these patients.
but not in patients (rho 5 20.25, NS). Nitroglycerin- A recent observation suggests that endothelial nitric
mediated vasodilation did not correlate with brachial oxide release can improve arterial compliance in hyper-
artery diameter in either group (rho , 0.01 for control tensive and normotensive humans [22]. However, studies
subjects, and rho 5 0.08 for patients, both NS). on endothelial dysfunction and impaired mechanical ves-
There was no significant correlation between time sel wall properties in various disease states failed to dem-
after transplantation and brachial artery flow-mediated onstrate a link between the two variables. Studies in
vasodilation or distensibility. hypercholesterolemic humans showed impaired femoral
artery endothelial function; however, they show no alter-
Comparison of renal allograft recipients with and ations of carotid and femoral artery elastic properties
without cyclosporine therapy [23]. Zenere et al found impaired flow-mediated vasodi-
Brachial artery flow-mediated vasodilation and disten- lation; however, no changes of the distensibility of the
sibility were similarly reduced in renal allograft recipi- femoral artery in patients with diabetes mellitus were
ents treated with azathioprine and prednisolone when shown [24]. VanGuldener et al observed impaired bra-
compared with patients receiving cyclosporine therapy chial artery flow-mediated vasodilation in hemodialysis
matched for age, sex, and serum creatinine levels (Ta- patients as compared with normal subjects, whereas the
reduction of the common carotid artery distensibilityble 4).
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coefficient failed to reach statistical significance [10]. In calcium antagonists have been shown to improve endo-
thelial function [30–32] and arterial distensibility [33,both the patient and control groups, distensibility was
not related to endothelium-dependent vasodilation. We 34]. Both b blockers [33] and loop diuretics [35] do not
influence arterial distensibility. An adverse effect on en-observed impairments of both endothelial function and
elastic vessel wall properties after renal transplantation. dothelial function also has not yet been demonstrated
for these substances. In the studied patients, pronouncedWe observed a significant correlation between brachial
artery flow-mediated dilation and distensibility when reductions of brachial artery flow-mediated vasodilation
and distensibility were observed independent of the anti-both groups were analyzed together. However, on sepa-
rate analysis of each group, flow-mediated vasodilation hypertensive drugs used. Hypercholesterolemia has been
shown to adversely influence both endothelial functiondid not appear to be related to arterial distensibility.
Elevated distending pressure and structural changes [36, 37] and arterial distensibility [38]. We observed sig-
nificantly elevated serum concentrations of total choles-of the arterial wall in patients with renal failure and
hypertension are often associated with an increase in terol and LDL cholesterol. Nevertheless, differences in
brachial artery flow-mediated vasodilation and distensi-vessel wall diameter [6, 25]. In this study, patients had
significantly elevated brachial artery diameters as com- bility between patients and control subjects remained
statistically significant after correction for serum choles-pared with control subjects. The elevated brachial artery
diameter may be the result of structural vessel wall terol levels. Animal studies indicate that cyclosporine
therapy may exert negative effects on endothelial func-changes, which could lead to a reduced vasodilator ca-
pacity and could therefore explain the observed alter- tion [39]. However, we found similarly decreased bra-
chial artery flow-mediated vasodilation and distensibilityations of distensibility and flow-mediated vasodilation.
However, because brachial artery dilation in response in both renal transplant recipients with and without
cyclosporine therapy. Our observation is supported byto glycerol trinitrate was similar in patients and control
subjects, the observed alterations of brachial artery flow- van den Dorpel et al, who reported that cyclosporine
withdrawal did not influence endothelial function inmediated vasodilation and distensibility in renal allograft
recipients cannot be attributed to a reduced arterial vaso- transplant patients [40].
dilator capacity. Subgroups of patients and control sub-
Conclusionjects matched for brachial artery end-diastolic diameter
with similar brachial artery mean blood flow velocities The results show impaired endothelial function and
also differed significantly in flow-mediated vasodilation. distensibility of the brachial artery in renal transplant
Therefore, the impaired brachial artery flow-mediated recipients with excellent graft function and without clini-
vasodilation in renal allograft recipients also cannot be cal evidence of atherosclerotic disease independent of
attributed to differences in brachial artery mean blood blood pressure level, cyclosporine therapy, dyslipidemia,
flow velocity during reactive hyperemia between patients and arterial dilatation. In contrast, endothelium-inde-
and control subjects. pendent vasodilation was preserved in renal allograft
Several factors may contribute to the observed alter- recipients. Thus, in this study, impaired endothelial func-
ations of mechanical vessel wall properties and endothe- tion and distensibility of the brachial artery cannot be
lial function. Uremia could impair arterial distensibility attributed to a diminished vasodilator capacity.
[5–7] and endothelial function [9, 10, 26, 27]. Endothelial
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